Speculators thought they would be better. Over 2.6 mill volume...

Speculators thought they would be better. Over 2.6 mill volume already.

Sydney - Wednesday - Sep 27: (RWE Australian Business News) -
Australian Pharmaceutical Industries Ltd (ASX code: API) has completed
an operational review and updated trading information for this year.
Sales have grown in the Retail division and have been maintained
in Pharmacy Distribution.
Earnings before interest, tax and depreciation (EBITD) in the
first half, and prior to one-off costs associated with finalising the
2006 full-year accounts, is expected to be lower than the EBITD of $29.6
million for continuing businesses in the first half last year.
The EBITD performance is traditionally stronger in the second
half, but is reliant on the success of the Christmas trading period.
The one-off costs incurred with the finalisation of the 2006
accounts to date are about $4.5 million.
This includes the cost of redundancies and consultants.
Net profit will be affected by increased depreciation in the
current year now that the Movex implementation is completed, and higher
interest costs as a result of deterioration in working capital
management, largely due to the delay in finalising the 2006 accounts.
This announcement was made after trading closed.